Suvratoxumab
- Generic Name
- Suvratoxumab
- Drug Type
- Biotech
- CAS Number
- 1629620-18-3
- Unique Ingredient Identifier
- 4L1997J4DF
- Background
Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
Aridis Pharmaceuticals Announces Asset Sale and Investment Proposal for Key Pipeline Candidates
• Aridis Pharmaceuticals has executed an agreement to sell AR-501, a therapeutic for chronic bacterial lung infections in cystic fibrosis, for $6.5 million plus royalties.
• The company is in discussions for an investment to fund the final Phase 3 study of AR-301, an adjunctive treatment for Ventilator Associated Pneumonia (VAP).
• A licensing dispute with MedImmune for AR-320, a VAP prevention candidate, remains unresolved, leading to the likely discontinuation of its Phase 3 trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath